177 related articles for article (PubMed ID: 37934368)
1. Identification of stably expressed microRNAs in plasma from high-grade serous ovarian carcinoma and benign tumor patients.
Petersen PHD; Lopacinska-Jørgensen J; Høgdall CK; Høgdall EV
Mol Biol Rep; 2023 Dec; 50(12):10235-10247. PubMed ID: 37934368
[TBL] [Abstract][Full Text] [Related]
2. Strategies for data normalization and missing data imputation and consequences for potential diagnostic microRNA biomarkers in epithelial ovarian cancer.
Lopacinska-Jørgensen J; Petersen PHD; Oliveira DVNP; Høgdall CK; Høgdall EV
PLoS One; 2023; 18(5):e0282576. PubMed ID: 37141239
[TBL] [Abstract][Full Text] [Related]
3. Blood Plasma Small Non-Coding RNAs as Diagnostic Molecules for the Progesterone-Receptor-Negative Phenotype of Serous Ovarian Tumors.
Timofeeva AV; Fedorov IS; Asaturova AV; Sannikova MV; Tregubova AV; Mayboroda OA; Khabas GN; Frankevich VE; Sukhikh GT
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569592
[TBL] [Abstract][Full Text] [Related]
4. Identification and validation of endogenous control miRNAs in plasma samples for normalization of qPCR data for Alzheimer's disease.
Dakterzada F; Targa A; Benítez ID; Romero-ElKhayat L; de Gonzalo-Calvo D; Torres G; Moncusí-Moix A; Huerto R; Sánchez-de-la-Torre M; Barbé F; Piñol-Ripoll G
Alzheimers Res Ther; 2020 Dec; 12(1):163. PubMed ID: 33278902
[TBL] [Abstract][Full Text] [Related]
5. Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues.
Bignotti E; Calza S; Tassi RA; Zanotti L; Bandiera E; Sartori E; Odicino FE; Ravaggi A; Todeschini P; Romani C
J Cell Mol Med; 2016 Dec; 20(12):2341-2348. PubMed ID: 27419385
[TBL] [Abstract][Full Text] [Related]
6. Identification and validation of reference genes for the detection of serum microRNAs by reverse transcription-quantitative polymerase chain reaction in patients with bladder cancer.
Wang L; Liu Y; Du L; Li J; Jiang X; Zheng G; Qu A; Wang H; Wang L; Zhang X; Liu H; Pan H; Yang Y; Wang C
Mol Med Rep; 2015 Jul; 12(1):615-22. PubMed ID: 25738263
[TBL] [Abstract][Full Text] [Related]
7. Exosomal miR-1290 is a potential biomarker of high-grade serous ovarian carcinoma and can discriminate patients from those with malignancies of other histological types.
Kobayashi M; Sawada K; Nakamura K; Yoshimura A; Miyamoto M; Shimizu A; Ishida K; Nakatsuka E; Kodama M; Hashimoto K; Mabuchi S; Kimura T
J Ovarian Res; 2018 Sep; 11(1):81. PubMed ID: 30219071
[TBL] [Abstract][Full Text] [Related]
8. Potential biomarker of circulating hsa-miR-1273g-3p level for detection of recurrent epithelial ovarian cancer.
Günel T; Gumusoglu E; Dogan B; Ertem FB; Hosseini MK; Cevik N; Senol T; Topuz S; Aydinli K
Arch Gynecol Obstet; 2018 Dec; 298(6):1173-1180. PubMed ID: 30264202
[TBL] [Abstract][Full Text] [Related]
9. [Identification of key molecules in miRNA-mRNA regulatory network associated with high-grade serous ovarian cancer recurrence using bioinformatic analysis].
Zhang P; He M; Zeng Y; Cai X
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Jan; 43(1):8-16. PubMed ID: 36856205
[TBL] [Abstract][Full Text] [Related]
10. Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts.
Todeschini P; Salviato E; Paracchini L; Ferracin M; Petrillo M; Zanotti L; Tognon G; Gambino A; Calura E; Caratti G; Martini P; Beltrame L; Maragoni L; Gallo D; Odicino FE; Sartori E; Scambia G; Negrini M; Ravaggi A; D'Incalci M; Marchini S; Bignotti E; Romualdi C
Cancer Lett; 2017 Mar; 388():320-327. PubMed ID: 28017893
[TBL] [Abstract][Full Text] [Related]
11. Integrated microRNA and mRNA signatures associated with overall survival in epithelial ovarian cancer.
Lopacinska-Jørgensen J; Oliveira DVNP; Wayne Novotny G; Høgdall CK; Høgdall EV
PLoS One; 2021; 16(7):e0255142. PubMed ID: 34320033
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Data Normalization Strategies for Array-Based MicroRNA Profiling Experiments and Identification and Validation of Circulating MicroRNAs as Endogenous Controls in Hypertension.
Chekka LMS; Langaee T; Johnson JA
Front Genet; 2022; 13():836636. PubMed ID: 35432462
[No Abstract] [Full Text] [Related]
13. Addressing the unsolved challenges in microRNA-based biomarker development: Suitable endogenous reference microRNAs for SARS-CoV-2 infection severity.
Belmonte T; Perez-Pons M; Benítez ID; Molinero M; García-Hidalgo MC; Rodríguez-Muñoz C; Gort-Paniello C; Moncusí-Moix A; Madè A; Devaux Y; Martelli F; Ortega A; González J; Torres G; Barbé F; de Gonzalo-Calvo D
Int J Biol Macromol; 2024 Jun; 269(Pt 2):131926. PubMed ID: 38688344
[TBL] [Abstract][Full Text] [Related]
14. Identification of serum miR-1246 and miR-150-5p as novel diagnostic biomarkers for high-grade serous ovarian cancer.
Niemira M; Erol A; Bielska A; Zeller A; Skwarska A; Chwialkowska K; Kuzmicki M; Szamatowicz J; Reszec J; Knapp P; Moniuszko M; Kretowski A
Sci Rep; 2023 Nov; 13(1):19287. PubMed ID: 37935712
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-625-3p improved proliferation and involved chemotherapy resistance via targeting PTEN in high grade ovarian serous carcinoma.
Zhong L; Liu X; Wang L; Liu Y; Zhang D; Zhao Y
J Ovarian Res; 2022 Jan; 15(1):7. PubMed ID: 35027053
[TBL] [Abstract][Full Text] [Related]
16. MiR-585-3p suppresses tumor proliferation and migration by directly targeting CAPN9 in high grade serous ovarian cancer.
Lu X; Li G; Liu S; Wang H; Chen B
J Ovarian Res; 2021 Jul; 14(1):90. PubMed ID: 34238324
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features.
Lee H; Park CS; Deftereos G; Morihara J; Stern JE; Hawes SE; Swisher E; Kiviat NB; Feng Q
World J Surg Oncol; 2012 Aug; 10():174. PubMed ID: 22925189
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive Profiling of Hypoxia-Related miRNAs Identifies miR-23a-3p Overexpression as a Marker of Platinum Resistance and Poor Prognosis in High-Grade Serous Ovarian Cancer.
Todeschini P; Salviato E; Romani C; Raimondi V; Ciccarese F; Ferrari F; Tognon G; Marchini S; D'Incalci M; Zanotti L; Ravaggi A; Odicino F; Sartori E; D'Agostino DM; Samaja M; Romualdi C; Bignotti E
Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34283087
[TBL] [Abstract][Full Text] [Related]
19. Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker.
Vilming Elgaaen B; Olstad OK; Haug KB; Brusletto B; Sandvik L; Staff AC; Gautvik KM; Davidson B
BMC Cancer; 2014 Feb; 14():80. PubMed ID: 24512620
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA Expression Profiles in Human Samples and Cell Lines Revealed Nine miRNAs Associated with Cisplatin Resistance in High-Grade Serous Ovarian Cancer.
Flores-Colón M; Rivera-Serrano M; Reyes-Burgos VG; Rolón JG; Pérez-Santiago J; Marcos-Martínez MJ; Valiyeva F; Vivas-Mejía PE
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
